Observe that Tev-Tropin is on the top of the list. Then look down to Neutroval and Neugranin. Study Neutroval in TEVA litigation this summer noting TEVA filed an ANDA and court decision. Then Larry, after you discover about Neutroval, learn how Nypro is the key supplier for Antares-TEVA and the connection to SICOR. Then read up on Lovenox and Zyprexa. You'll begin to discover that Antares is the preferred exclusive license provider for TEVA biosimilar program: Neutroval, Neugranin, etc. BTW, TEVA has been funding Antares for scale-up which is the step before manufacturing via Nypro.
btw, i view catalysts are pps movers -- great libigel efficacy will drive this pps to above 3
hope this helps. i'll offer you more links if you want.
Approval Of Anturol Is A Major Positive For Antares [View article]
Wow! Yer on a roll with Antares! (smile)
However, the next big catalyst is Libigel, not the epinephrine medicament, and Sumatriptan is one of the more unlikely candidates if you discover as I have what TEVA has already filed for with the FDA. I suggest you review TEVA's CFO's presentation in June 2011 where the TEVA pyramid biosimilar food chain is spelled out in black & white. Have you looked at a summer litigation regarding TEVA and an ANDA injection drug?
Did you also know that the Population Council and one of Antares's VPs are appearing at a conference in Q1 2012 related to NestraGel? Or that CEO Wotton is promising a new VIBEX project in the near-term? Or that Antares has contracted with Nypro to make millions of VIBEX injectors? Or that the company has not re-signed for its headquarter's lease in NJ?
Trust me, epinephrine isn't the "next catalyst" not by a long shot. It's LibiGel, and/or the many other items I've listed.
Antares Pharma's Anturol Approaches PDUFA Date [View article]
Smitty, I hope you answer posts to your articles. Biomaster asks a fair question. I add a second question: How do you know Watson is going to take Gelnique off the market? I have never read that and would like you to reveal your source. I don't think you will, but am otherwise hopeful of being proved wrong. SL
Investors And Traders In The Biotech Landscape [View article]
Ah yes AIS. Interesting really. You focus on LibiGel, when as you know, that's just 1 of many, many revenue generating catalysts. Great article! Wow! SL
Antares Pharmaceuticals: A Buy Based On Exceptional New Product Outlook [View article]
Good for you Smitty! An intelligent piece of writing. I hope you become the #1 writer for Pharmaceuticals with SA. Congratulations on waking up the Market to the next big winner! Bravo! SL
New Drug Approvals Make Or Break Biotechnology Stocks [View article]
yAZZBro, that link i posted highlights key information with a further link to the Antares' Dec presentation page. We'll just have to agree to disagree about insider buying; I've seen too many CEOs do it to exploit shareholders. BTW, AIS is up today.
New Drug Approvals Make Or Break Biotechnology Stocks [View article]
Todd, I'm not sure I use 'Insider buys' as a variable to microcap biotech stock picking given that I've also seen one too many CEOs use buying as ploy at penny price levels. Personally, I see Insider buys as neither a vote of confidence nor a lack of confidence. But to each his/her own. Interesting perspective. Thanks.
New Drug Approvals Make Or Break Biotechnology Stocks [View article]
Interesting Yazzbro. "If" is a conditional word in the English language and given that Anturol's decision is yet to be announced, it's "if". Rather than focus on Insider Trading, why not highlight that one Board Member is the CEO of Spectrum, a stellar company. How many shares Insiders hold is not a measure I put much stock into, but I do put stock into the science. I've seen you 'bash' before Yazzbro and I'm not impressed. But maybe this link will impress Todd's readers: http://seekingalpha.co... Antares has been on a net positive path for 3 years. Fact.
Keeping An Eye On Both BioSante And Antares Pharma [View article]
Let's stick to AIS Brigars6 as that is the story of the moment. Once again Mr. Garza has distinguished himself with a lasar-like acumen for bringing Antares out from the shadows as the power-house it's going to be and has started to be already. In fact, during my tenure with ZLCS it doubled, but management failed and the market caught them with their Exalgo pants down. Which is how Antares is so strikingly different as I as a newbie drank from the well of Sir Tappy's knowledge before thirsting and hungering for more which drove me to read nearly every patent, every scholarly article, and every SEC filing, as well as digging into the deep files of Australia and back, and all coming away realizing Antares suffered from one defect: market visibility. But that too apparently changed in Q3 as institutions came piling in along with increased 'short' interest and investors like myself who have that rare gift to discern the creme from the corn. Of course Sir Tappy's departure from Yahoo struck a blow to his fans, I myself among them, but my wager is he is quite confident in his investment and I for one wouldn't think for a moment to disagree with this Yahoo giant.
Keeping An Eye On Both BioSante And Antares Pharma [View article]
Mr. Garza,
I too concur with this fellow called Tappy. This gentleman has a keen understanding of Antares dynamics bar none. I was rapidly brought up to speed by this gentleman after-which I launched into my usual foray of due-diligence, only to discover that I am as yet to find a hole in his thesis. As you referenced my own work in your BioMedReports article, you know Mr. Garza that I specialize in identifying the creme de la creme with the boldness to change my mind if the facts counter my working knowledge. However, in this case, I concur with this astute investor named Tappy. Antares has too many irons in the fire to be described as a typical microcap risk; it is more like a microcap that is poised to move to the next level. Double digits in 2012 is a likely possibility. Near-term upside is, and forgive my use of this flamboyant word, illustrious.
That you Mr. Garza for your astute and thought-provoking coverage.
1 Biotech To Buy And 6 FDA Decision-Pending Biotechs To Avoid [View article]
Here's another pipeline caveat. In 2012, Antares will file an NDA for its VIBEX methotrexate automated injector. The use of methotrexate for rheumatoid arthritis is already approved and has a long history. Rheumatologists, if you read scholarly journals, are eager for a less intrusive/painful injector system for a medicament that is often injected with pain and apprehension by the user. Antares's VIBEX injector will be the first with patent protection secured to address a need rheumatoligists are on record for--as it stands, Antares owns 100% of this technology which by the way is why TEVA is in-house buying the manufacturing equipment for Antares (see Qs) for a separate VIBEX project. This, from a financial perspective, is foreseeable in the short-term (market 2013) and Antares already has an HGH injectable in the market.
Approval Of Anturol Is A Major Positive For Antares [View article]
Here's a link for you - go to slide 40 - http://bit.ly/tHzh3T
Observe that Tev-Tropin is on the top of the list. Then look down to Neutroval and Neugranin. Study Neutroval in TEVA litigation this summer noting TEVA filed an ANDA and court decision. Then Larry, after you discover about Neutroval, learn how Nypro is the key supplier for Antares-TEVA and the connection to SICOR. Then read up on Lovenox and Zyprexa. You'll begin to discover that Antares is the preferred exclusive license provider for TEVA biosimilar program: Neutroval, Neugranin, etc. BTW, TEVA has been funding Antares for scale-up which is the step before manufacturing via Nypro.
btw, i view catalysts are pps movers -- great libigel efficacy will drive this pps to above 3
hope this helps. i'll offer you more links if you want.
Approval Of Anturol Is A Major Positive For Antares [View article]
Approval Of Anturol Is A Major Positive For Antares [View article]
BTW, the next catalyst is Libigel, not VIBEX epinephrine.
Approval Of Anturol Is A Major Positive For Antares [View article]
However, the next big catalyst is Libigel, not the epinephrine medicament, and Sumatriptan is one of the more unlikely candidates if you discover as I have what TEVA has already filed for with the FDA. I suggest you review TEVA's CFO's presentation in June 2011 where the TEVA pyramid biosimilar food chain is spelled out in black & white. Have you looked at a summer litigation regarding TEVA and an ANDA injection drug?
Did you also know that the Population Council and one of Antares's VPs are appearing at a conference in Q1 2012 related to NestraGel? Or that CEO Wotton is promising a new VIBEX project in the near-term? Or that Antares has contracted with Nypro to make millions of VIBEX injectors? Or that the company has not re-signed for its headquarter's lease in NJ?
Trust me, epinephrine isn't the "next catalyst" not by a long shot. It's LibiGel, and/or the many other items I've listed.
Antares Pharma's Anturol Approaches PDUFA Date [View article]
Antares Pharmaceuticals: A Buy Based On Exceptional New Product Outlook [View article]
Investors And Traders In The Biotech Landscape [View article]
Antares Pharmaceuticals: A Buy Based On Exceptional New Product Outlook [View article]
New Drug Approvals Make Or Break Biotechnology Stocks [View article]
New Drug Approvals Make Or Break Biotechnology Stocks [View article]
New Drug Approvals Make Or Break Biotechnology Stocks [View article]
Keeping An Eye On Both BioSante And Antares Pharma [View article]
I think the same as Tappy.
BEST WISHES
Keeping An Eye On Both BioSante And Antares Pharma [View article]
Keeping An Eye On Both BioSante And Antares Pharma [View article]
I too concur with this fellow called Tappy. This gentleman has a keen understanding of Antares dynamics bar none. I was rapidly brought up to speed by this gentleman after-which I launched into my usual foray of due-diligence, only to discover that I am as yet to find a hole in his thesis. As you referenced my own work in your BioMedReports article, you know Mr. Garza that I specialize in identifying the creme de la creme with the boldness to change my mind if the facts counter my working knowledge. However, in this case, I concur with this astute investor named Tappy. Antares has too many irons in the fire to be described as a typical microcap risk; it is more like a microcap that is poised to move to the next level. Double digits in 2012 is a likely possibility. Near-term upside is, and forgive my use of this flamboyant word, illustrious.
That you Mr. Garza for your astute and thought-provoking coverage.
Very best to you,
SL
1 Biotech To Buy And 6 FDA Decision-Pending Biotechs To Avoid [View article]